MTOR and arthritic joint disease: Thus, we speculate that the additive therapeutic effects we observed in the SKG arthritis model might be explained by the inhibition of glutamine metabolism at the same time that mTOR signaling and mTOR-induced glycolysis were also inhibited, but further investigation is necessary to determine the metabolic profiles involved.